Tag: The Lancet

Upadacitinib ‘safe and effective’ for the treatment of active non-radiographic axial...

Upadacitinib (AbbVie), a Janus kinase inhibitor, significantly improves the signs and symptoms of non-radiographic axial spondyloarthritis compared with placebo at 14 weeks, according to...

Vertebroplasty trumps placebo in treatment of painful spinal fractures

On 17 August, a multicentre, randomised, double-blind, placebo-controlled trial—the VAPOUR trial—was published online ahead of print in The Lancet. Six-month data from the trial...